secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-010507
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports preliminary cash >$500M as of Dec 31, 2025
--------------------------------------------------------

- Preliminary unaudited cash, equivalents and marketable securities exceed $500M (subject to year-end close).
- No other financial results disclosed; annual 10-K filing pending.
- Investor presentation posted on company website as of January 12, 2026.
- Cash position provides runway for ongoing breast cancer pipeline development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526010507/0001193125-26-010507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526010507/olma-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-010507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer